



REMARKS

The specification has been amended to state that this application claims priority from provisional application No. 60/232,669, filed September 18, 2000.


The claims have been amended to place them in proper form for U.S. examination. In particular, multiple dependencies have been eliminated. Also, claim 9 has been converted from a European style "use" claim to a method-of-treatment claim in accordance with standard US format. The claim has also been re-worded slightly, to make the claim wording parallel with that of claim 1.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version With Markings To Show Changes".

A Notice of Allowance is courteously solicited.

Respectfully submitted,

Date: August 10, 2001

  
James T. Jones  
Attorney for Applicant  
Reg. No. 30,561

Pfizer Inc  
Patent Department  
Eastern Point Road  
Groton, CT 06340  
(860) 441-4903

## VERSION WITH MARKINGS TO SHOW CHANGES

In the specification:

The following sentence has been entered as the first paragraph immediately following the title:

This application is filed claiming priority from co-pending United States Provisional Application No. 60/232,669 filed September 15, 2000.

Claim 2 has been canceled.

3. A method or use as claimed in claim 1 [ or 2], wherein the inhibitor is administered orally or topically.
4. A method [ or use] as claimed in claim 1 [any preceding claim], wherein the [wherein the] inhibitor has an IC50 at less than 100 nanomolar.
6. A method [ or use] as claimed in claim 1 [ any preceding claim], wherein the inhibitor is sildenafil.
9. A method of treating wounds in a patient which comprises treating the patient with an effective amount [ The use] of a cGMP PDE5 inhibitor in combination with a matrix metalloprotease inhibitor (MMP), and/or a urokinase type plasminogen activator inhibitor (uPA), [for the manufacture of a medicament for the treatment of wounds,] wherein the wound type is selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.
10. A method [ Use] as claimed in claim 9, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.

0927344 081001